Your browser doesn't support javascript.
loading
Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy.
Fürstenau, Moritz; Hopfinger, Georg; Robrecht, Sandra; Fink, Anna-Maria; Al-Sawaf, Othman; Langerbeins, Petra; Cramer, Paula; Tresckow, Julia Von; Maurer, Christian; Kutsch, Nadine; Hoechstetter, Manuela; Dreyling, Martin; Lange, Elisabeth; Kneba, Michael; Stilgenbauer, Stephan; Döhner, Hartmut; Hensel, Manfred; Kiehl, Michael G; Jaeger, Ulrich; Wendtner, Clemens-Martin; Goede, Valentin; Fischer, Kirsten; von Bergwelt-Baildon, Michael; Eichhorst, Barbara; Hallek, Michael; Theurich, Sebastian.
Afiliação
  • Fürstenau M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany. moritz.fuerstenau@uk-koeln.de.
  • Hopfinger G; Department of Internal Medicine I, Bone Marrow Transplantation, Medical University of Vienna, Vienna, Austria.
  • Robrecht S; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
  • Fink AM; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
  • Al-Sawaf O; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
  • Langerbeins P; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
  • Cramer P; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
  • Tresckow JV; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
  • Maurer C; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
  • Kutsch N; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
  • Hoechstetter M; Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, München Klinik Schwabing, Munich, Germany.
  • Dreyling M; Department of Medicine III, University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
  • Lange E; Evangelisches Krankenhaus Hamm, Hamm, Germany.
  • Kneba M; Department II of Internal Medicine, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Stilgenbauer S; Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
  • Döhner H; Department of Hematology, Oncology and Rheumatology and José Carreras Center for Immuno and Gene Therapy, Saarland University Medical School, Homburg/Saar, Germany.
  • Hensel M; Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
  • Kiehl MG; Mannheim Oncology Practice, Mannheim, Germany.
  • Jaeger U; Department of Internal Medicine, Frankfurt (Oder) General Hospital, Frankfurt/Oder, Germany.
  • Wendtner CM; Department of Medicine I, Clinical Division of Hematology and Hemostaseology and Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria.
  • Goede V; Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, München Klinik Schwabing, Munich, Germany.
  • Fischer K; Oncogeriatric Unit, Department of Geriatric Medicine, St. Marien Hospital, Cologne, Germany.
  • von Bergwelt-Baildon M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
  • Eichhorst B; Department of Medicine III, University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
  • Hallek M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
  • Theurich S; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany.
Leukemia ; 34(4): 1177-1181, 2020 04.
Article em En | MEDLINE | ID: mdl-31728057
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica / Imunoterapia / Obesidade Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Determinantes_sociais_saude Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica / Imunoterapia / Obesidade Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Determinantes_sociais_saude Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Ano de publicação: 2020 Tipo de documento: Article